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Primary dysmenorrhoea can be correlated with Kashtartava which is 
characterized by painful menstruation. According to Ayurveda, pain is an 
indication of Vata Vikriti – ‘Na hi vaatadrite Shoolam’. Apana Vayu has been 
given prime importance in Gynecological disorders. Normal menstruation 
is the function of the Apanavata, so painful menstruation is considered as 
Apanavatadushti. Vyana Vata has control over the muscles which brings 
about actions such as contraction, relaxation, extension, flexion etc. 
According to Acharya Charaka, Vata plays a key role in all types of Yoni 
Roga. As Vata is the main causative factor, it should be treated first. 
According to Acharya Vagbhata all measures capable of suppressing Vata 
are indicated. Till date, no successful advances have been made in the 
management of Primary dysmenorrhoea by conventional medicine. The 
best evidence-based treatments are NSAIDs and hormonal contraceptives 
but they have a lot of side effects. Owing to the gravity of the situation, need 
is felt for search of safe/more effective, palatable oral dosage forms to 
reduce pain during menstrual period. A systematic review of studies in 
developing countries performed by Harlow and Campbell has revealed that 
about 25-50% of adult women and about 75% of adolescents experience 
pain during menstruation. It is a randomized comparative clinical trial with 
30 patients fulfilling the inclusion criteria were selected for the trial. The 
selected patients were randomly divided into 2 groups, 15 patients each. 
The duration of treatment was from 7th day due date of menstrual cycle to 
next menstrual cycle for 60 days. The assessment was done after each cycle 
on 5th day of cycle and follow-up for the next menstrual cycle. The test of 
significance showed that the efficacy of Hingvadi churna is more than 
Rajahpravartini vati in Kashtartava. 
 
INTRODUCTION
Dysmenorrhoea is the most common 
gynaecological problem faced by women during 
their adolescence which causes significant 
discomfort and anxiety for the woman as well as 
family. Dysmenorrhoea itself is not life threatening, 
but is found to have a profound impact on the daily 
activities and may result in missing work or school, 
inability to participate in sports or other activities. 
Thereby, it may accentuate the emotional distress 
brought on by the pain[1]. 
Not less than 50% of women are said to 
experience some discomfort in relation to 
menstruation, and 5-10% of girls in their late teens 
and early twenties are incapacitated for several 
hours each month. Estimates vary widely because of 
difference in the criteria of dysmenorrhoea and 
because most investigations concern only one 
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section of the community. The incidence of 
dysmenorrhoea is affected by social status, 
occupation and age, so groups of school girls, 
college students, factory workers, and women 
members of armed forces each provide different 
statistics.[2] 
In Ayurveda dysmenorrhoea is not 
described as a separate disease entity. It can be 
because women were not suffering much from this 
problem those days because of pin pointed 
Ritucharya and Rajasvalacharya. Though word 
Kashtartava is not separately described as a disease 
in Ayurvedic classics there are many other diseases 
in which Kashtartava is considered and is described 
as a symptom. Hence, this study is particular about 
the description regarding Kashtartava on the basis 
of scattered classical references. 
AIMS AND OBJECTIVES 
 To study aetiopathogenesis of Kashtartava and 
to explore the clinical consequences. 
 To evaluate the effect of Hingvadi Churna in 
dysmenorrhoea. 
 To evaluate the effect of the Rajah Pravartini vati 
in dysmenorrhoea. 
 To compare the efficacy of trial drugs in the 
management of dysmenorrhoea. 
MATERIAL AND METHODS 
Ethical Clearance 
Design of the Study: The method adopted in 
present study is randomized, clinical, open study. 
Selection of Cases: Total 30 clinically diagnosed 
and confirmed cases of Primary Dysmenorrhoea 
were registered from the O.P.D./I.P.D., N.I.A. 
Hospital, Jaipur. 
Inclusion Criteria: Participants coming with chief 
complaint of Kashtartava with scanty or average 
amount of menses, Participants in age group of 14 
to 30 years, Participants suffering with Kashtartava 
for more than 2 consecutive cycles. 
Exclusion Criteria: Participants suffering from 
secondary dysmenorrhoea, STIs, systemic diseases, 
Participants having organic pathology of uterus and 
adnexa e.g. Fibroid uterus, carcinoma of 
endometrium etc, Participants having Dysfunctional 
Uterine Bleeding, Participants with H/O Thyroid 
dysfunction. 
Investigations: Laboratory investigations were 
carried out before treatment to rule out any other 
pathological conditions 
Haematological: CBC, HIV, HbsAg, VDRL, Random 
blood sugar, Monteux test (if needed), Thyroid 
profile (if needed).  
Urine: Routine and microscopic examination. 
Sonography (U.S.G.): For uterine and adnexal 
study (if needed) to rule out any pathology or 
lesion. 
Posology: Patients included in the present study 
are randomly divided into following two groups: 
 Group-A Group-B 
Drug Hingvadi Churna Rajah-Pravartini-
Vati 
Dose 3gm twice a day 
with lukewarm 
water 
500mg twice a 
day with 
lukewarm water 
Route Oral Oral 








Duration for clinical trial 
  The trial will be carried out for 60days in 
two consecutive menstrual cycles.  
Follow up study 
Case will be followed during trial fortnightly 
for 2 consecutive menstrual cycles. Clinical 
assessment will be done after completion of third 
consecutive menstrual cycles. 
Criteria of Assessment 
Assessment of Pain (Dysmenorrhoea): A special Scoring Pattern was applied in symptoms: 
Pain Intensity Grade 
Absent 0 
Mild (pain do not interfere with daily activity) 1 
Moderate (daily activity hampers, relieves with analgesics) 2 




Pain for one day (for few hours) 1 
Pain for one day (for whole day) 2 
Pain for>or=2 days 3 
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Menstrual Flow Duration Grade 
1 day 0 
< or =2 days 1 
3-4 days 2 
> or =5 days 3 
  
Menstrual Flow Amount Grade 
Scanty (spotting) 0 
Average (1-2 pads) 1 
Normal (3-4 pads) 2 
Excessive (5 pads or more) 3 
Visual Analog Scale 
         
           1  2    3       4           5               6           7           8             9              10 
Worst pain  
Imaginable and further it is assessed as follows 
7 - 10 Severe Pain Grade 0 
6 - 4 Moderate Pain Grade 1 
1 - 3 Mild Pain Grade 2 
0 No Pain Grade 3 
Associated complaints: Total 10 complaints 
7 -10 grade 0 
4 - 6 grade 1 
1 - 3 grade 2 
0 grade 3 
Rating Scale for the Assessment of Improvement in the Symptoms After Therapy 
Percentage of Relief Effect 
No relief 0% relief in the signs and symtoms 
Mild relief (1 to ≤ 25%) relief in the signs and symtoms 
Moderate Relief (>25 to ≤ 50%) relief in the signs and symtoms 
Significant relief (>50 to ≤ 75%) relief in the signs and symtoms 
Excellent Relief (>75%) relief in the signs and symtoms 
Statistical Evaluation of results 
Further the effect of the treatment of signs and symptoms were analyzed statistically by Mean, SD, 
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OBSERVATIONS AND RESULTS 
Table 1: Shows the pattern of clinical recovery in various Subjective Parameters of Kashtartava in 15 
patients treated with Hingvadi Churna orally- Group A by Wilcoxon-ranks test matched-pairs signed-
ranks test 
 Highly significant results are shown on Pain Intensity, Pain Duration, Nature of Pain, Associated 
symptoms and VAS Scale. Results on Flow Duration and amount of flow were not significant. 
Table 2: Shows the pattern of clinical recovery in various Associated Symptoms of Kashtartava in 15 
patients treated with Hingvadi Churna orally- Group A by Wilcoxon matched-pairs signed-ranks test 
 Highly significant results are shown on Nausea, Fatigue, Breast tenderness and Giddiness. Significant 
results obtained on Sweat, Headache and Constipation. Results on Fainting, Vaginal discharge, Vomiting and 
Diarrhoea were Non-significant. 
Table 3: Shows the pattern of clinical recovery in various Subjective Parameters of Kashtartava in 15 






SD SE P Results 
BT AT 
1.  Pain Intensity 2.467 1.333 1.133 53.91% 0.7432 0.1919 <0.0001 H.S. 
2.  Pain Duration 2.467 1.133 1.333 54.03% 0.7237 0.1869 < 0.0001 H.S. 
3.  Nature of Pain 2.333 0.93333 1.400 60.00% 0.6325 0.1633 <0.0001 H.S. 
4.  Associated Symptoms 2.000 0.6000 1.400 70% 0.7368 0.1902 <0.0001 H.S. 
5.  VAS Scale 2.467 0.9333 1.533 62.14% 0.6399 0.1652 < 0.0001 H.S. 
6.  Flow Duration 1.733 2.133 -0.400 -23.08% 0.6325 0.1633 >0.05 N.S. 
7.  Flow Amount 1.533 1.929 -0.4286 -26.66% 0.7559 0.2020 >0.05 N.S. 
Highly significant results are shown on Pain Intensity, Pain Duration, Nature of Pain, Associated 
symptoms and VAS Scale. Results on Flow Duration and Flow Amount were Non-significant. 
 
S No Symptoms Mean Dif. % of 
Relief 
SD SE P Results 
BT AT 
1. Pain Intensity 2.40 3.40 1.00 83.33% 0.654 0.169 <0.0001 H.S. 
2. Pain Duration 2.33 0.40 1.93 82.85% 0.798 0.206 <0.0001 H.S. 
3. Nature of Pain 2.53 0.73 1.80 71.06% 0.676 0.174 <0.0001 H.S. 
4. Flow Duration 1.60 1.73 -0.13 8.33% 0.639 0.165 > 0.05 N.S. 
5. Flow Amount 1.46 1.53 -0.06 4.54% 0.593 0.153 > 0.05 N.S. 
6. Associated Symptoms 2.06 0.53 1.53 74.16% 0.639 0.165 <0.0001 H.S. 






SD SE P Results 
BT AT 
1.  Nausea 0.80 0.13 0.66 83.33% 0.48 0.12 <0.001 H.S. 
2.  Vomiting 0.40 0.13 0.26 66.67% 0.45 0.11  > 0.05 N.S. 
3.  Fatigue 0.86 0.13 0.73 84.60% 0.45 0.11 <0.001 H.S. 
4.  Headache 0.60 0.20 0.40 66.66% 0.50 0.13 < 0.05 S. 
5.  Fainting 0.26 0.13 0.13 49.98% 0.35 0.09 > 0.05 N.S. 
6.  Sweat 0.53 0.13 0.40 75.00% 0.50 0.13 < 0.05 S. 
7.  Diarrhoea 0.20 0.06 0.13 66.65% 0.35 0.090 > 0.05 N.S. 
8.  Constipation 0.80 0.33 0.46 58.33% 0.51 0.13 < 0.05 S. 
9.  Vaginal Discharge 0.13 0.06 0.06  50.01% 0.25 0.06 > 0.05 N.S. 
10.  Breast Tenderness 0.80 0.20 0.60 75.00% 0.50 0.13 < 0.001 H.S. 
11.  Giddiness 0.80 0.13 0.67 83.33% 0.48 0.12 < 0.001 H.S. 
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Table 4: Shows the pattern of clinical recovery in various Associated Symptoms of Kashtartava in 15 
patients treated with Rajah Pravartini Vati orally Group B by Wilcoxon matched-pairs signed-ranks test 
S.No. Symptoms Mean Dif. % of 
Relief 
SD SE P Results 
BT AT 
1.  Nausea 0.66 0.13 0.53 79.99% 0.51 0.13 < 0.001 H.S. 
2.  Vomiting 0.53 0.26 0.26 50.00% 0.45 0.11 > 0.05 N.S 
3.  Fatigue 0.93 0.20 0.73 78.57% 0.45 0.11 < 0.001 H.S. 
4.  Headache 0.46 0.06 0.40 85.7% 0.50 0.13 < 0.05 S. 
5.  Fainting 0.20 0.06 0.13 66.65% 0.35 0.09 > 0.05  N.S. 
6.  Sweat 0.66 0.13 0.53 79.99% 0.51 0.13 < 0.001 H.S. 
7.  Diarrhoea 0.13 0.06 0.06 50.01% 0.25 0.06 > 0.05 N.S. 
8.  Constipation 0.53 0.26 0.26 50.00% 0.45 0.11 > 0.05 N.S. 
9.  Vaginal Discharge 0.33 0.20 0.13 39.99% 0.35 0.09 > 0.05 N.S. 
10.  Breast Tenderness 0.66 0.20 0.46 70.00% 0.51 0.13 < 0.05 S. 
11.  Giddiness 0.80 0.40 0.40 50.00% 0.50 0.13 < 0.05 S. 
Highly significant results are shown on Nausea, Fatigue and Sweat. Significant results obtained on 
Headache, Breast tenderness and Giddiness. Results on Fainting, Vomiting, Diarrhoea, Constipation and 
Vaginal discharge were Non-significant. 
Table 5: Inter Group Comparison in Associated Symptoms of Kashtartava by Mann-Whitney Test 
Symptoms Group Mean Dif. S.D.± S.E.± P Result 
Nausea Group A 0.6667 0.4880 0.1260 >0.05 N.S. 
Group B 0.3333 0.4880 0.1260 
Vomiting Group A 0.2667 0.4577 0.1182 >0.05  N.S 
Group B 0.2667 0.4577 0.1182 
Fatigue Group A 0.7333 0.4577 0.1182 >0.05 N.S 
Group B 0.7333 0.4577 0.1182 
Headache Group A 0.2667 0.4577 0.1182 >0.05 N.S 
Group B 0.3333 0.4880 0.1260 
Fainting Group A 0.1333 0.3519 0.09085 >0.05 N.S 
Group B 0.1333 0.3519 0.09085 
Sweat Group A 0.4000 0.5071 0.1309 >0.05 N.S 
Group B 0.5333 05164 0.1333 
Diarrhoea Group A 0.1333 0.3519 0.09085 >0.05 N.S 
Group B 0.06667 0.2582 0.06667 
Constipation Group A 0.4667 0.5164 0.1333 >0.05 N.S 
Group B 0.2667 0.4577 0.1182 
Vaginal Discharge Group A 0.06667 0.2582 0.06667 >0.05 N.S 
Group B 0.1333 0.3519 0.09085 
Breast Tenderness Group A 0.6000 0.5071 0.1309 >0.05 N.S. 
Group B 0.4667 0.5164 0.1333 
Giddiness Group A 0.6667 0.4880 0.1260 >0.05  N.S. 
Group B 0.4000 0.5071 0.1309 
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Table 6: Inter Group Comparison in Subjective Parameters of Kashtartava by Mann-Whitney Test 
Symptoms Group Mean Dif. S.D.± S.E.± P Result 
Pain Intensity 
Group A 2.000 0.6547 0.1690 
< 0.001 H.S. 
Group B 1.133 0.7432 0.1919 
Pain Duration 
Group A 1.933 0.7988 0.2063 
>0.05 N.S. 
Group B 1.333 0.7237 0.1869 
Nature of Pain 
Group A 1.800 0.6761 0.1746 
>0.05 N.S. 
Group B 1.400 0.6325 0.1633 
Flow Duration 
Group A -0.1333 0.6399 0.1652 
>0.05 N.S. 
Group B -0.4000 0.6325 0.1633 
Flow Amount 
Group A -0.0667 0.5936 0.1533 
>0.05 N.S. 
Group B -0.4000 0.7368 0.1092 
Associated Symptoms 
Group A 1.533 0.6399 0.1652 
>0.05 N.S. 
Group B 1.400 0.7368 0,1902 
VAS Scale 
Group A 2.000 0.9258 0.2390 
< 0.001 H.S. 
Group B 0.9333 0.7988 0.2063 
Non-significant results were obtained in Pain Duration, Nature of Pain, Flow Duration and Flow 
Amount and associated symptoms. While highly significant result obtained in Pain intensity and VAS Scale in 
which Group A is better than Group B. 
Table 7: Shows the % Improvement of Symptoms in Both Groups 
S.NO. Cardinal Symptoms Result in Percentage 
  Group A Group B 
1 Nausea 83.33% 79.99% 
2 Vomiting 66.67% 50.00% 
3 Fatigue 84.60% 78.57% 
4 Headache 66.66% 85.7% 
5 Fainting 49.98% 66.65% 
6 Sweat 75.00% 79.99% 
7 Diarrhoea 66.65% 50.01% 
8 Constipation 58.33% 50.00% 
9 Vaginal Discharge 50.01% 39.99% 
10 Breast Tenderness 75.00% 70.00% 
11 Giddiness 83.33% 50.00% 
12 Pain Intensity 83.33% 53.91% 
13 Pain Duration 82.85% 54.03% 
14 Nature of Pain 71.06% 60.00% 
15 Flow Duration 08.33% 23.08% 
16 Flow Amount 04.54% 26.66% 
17 Associated Symptoms 74.16% 70% 
18 VAS Scale 76.92% 62.14% 
 Average % of relief 63.05% 52.84% 
Average Percentage of relief 
 Comparing the symptomatic improvement in both groups it was found that Average percentage of 
relief was higher in ‘Group A’ i.e. 63.05%, followed by ‘Group B’ i.e., 52.84%. It shows that effect of therapy 
was more in Group A in comparison to Group B. 
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Table 8: Overall Effect of Therapy 
S.No. Effect of therapy Result Group A Group B 
No. % No. % 
1 Mild (0 to 25%) 00 0.00% 00 0.00% 
2 Moderate (>25 to 50%) 01 06.66% 11 73.33% 
3 Significant (>50 to 75%) 11 73.33% 04 26.66% 
4 Excellent (>75%) 03 20.00% 00 0.00% 
DISCUSSION 
Mode of action of Hingvadi Churna8 
Drugs of Hingvadi Churna have 
predominantly Tikta, Katu, Kashaya and Amla Rasa. 
Tikta Rasa has Agni Vardhaka, Ruchya and Mukha 
Shodhaka properties, so it increases appetite and 
improves digestion. Kashaya Rasa has the property 
of Asravishodhana (Raktadushtihara). Amla Rasa of 
Matulung, has properties like Agnideeptikrut, 
Pachana and Rochana which improves digestion, 
increases appetite. Its Hridya property reduces 
nausea and vomiting. Amla Rasa also has the 
property of Muda Vata Anulomana (Mudam- 
Ananulomagam, Vata Mutra Purishaanaam 
Anulomanam). Katu Rasa, Usna Virya and Katu 
Vipaka of Yavakshar increases appetite and 
improves digestion which brings about 
Srotoshodhana.  
 Laghu and Ruksha gunas of the drugs of 
pacify Kapha vitiation if any. Sara, Ushna, Tikshna 
and Sookshma properties of the drugs in the 
formulation remove Avarana (Kapha) and thus 
allow normal movement of Apana Vata. Hingvadi 
Churna mostly contains drugs having Ushna Virya 
which pacifies vitiated Vata. Most of the drugs in 
the Yoga have Katu Madhura Vipaka which also 
pacifies vitiated Vata. Vata Anulomana, Shulahara, 
Shothahara, Srotovishodhana properties of drugs of 
Hingvadi churna facilitates normal flow of Vata i.e. 
Anuloma Gati of Apanavata. 
Mode of action of Rajah Pravirtini Vati9 
It is effective in Artavavikara. Hingu, Kumari, 
Tankan and Kasis are the main ingredients of Rajah 
Pravirtini Vati. Hingu (Ferula Asafoetida Linn) has 
Shoolahara (colic pain reliever) and Vatanulomana 
(facilitator of downward movement of Vata) 
property which helps in normalising the function of 
Apanvata, which is main causative factor of 
Kashtartava. Hingu has anti flatulent and digestive 
properties & counteracts spasmodic disorders and 
may probably supress the secretion of progesterone 
hormone[3]. The gum resin contains the coumarins, 
5-hydroxy-umbelliprenin, assafoetidin etc[4].  
Kumari (Aloe barbadensis Mill.) has a 
characteristic bitter taste and used mainly as 
purgative, improves digestion; the cathartic 
properties of aloes are attributed to the presence of 
a mixture of glycosides called ‘aloin’[5]. Kumari also 
contains beeta-sitosterol and has the anti-
prostaglandin activity[6]. Cathartic property of this 
relives the obstruction in the pathways of Vayu, and 
there by relieves spasm.  
Hingu, Tankana, Kasis are Artavajanana 
drugs. Kasis helps in Rakta Dhatu Vriddhi, which 
improve the uterine blood circulation (reduced 
blood circulation is a cause for dysmenorrhoea.) 
Balya (strength promoting) (Kumari, Hingu, 
Tankana, Kasis) Rasayana (Kumari) drugs give 
strength to uterine musculature for easy expulsion 
of Raja. Tankana is Garbhashaya sankochaka 
(improves the tonicity of uterine muscle) drug 
helps in normal harmonization during contraction. 
 Comparing the symptomatic improvement 
in both groups it was found that overall relief was 
higher in Group A followed by Group B i.e. 03 
(20.00%) patients having excellent relief, 11 
(73.33%) patients showed significant relief, 01 
(6.66%) patient showed moderate relief. In Group B 
01 (04.00%) patient showed excellent relief, 04 
(26.66%) patients showed significant relief, 11 
(73.33%) patients showed moderate relief. So the 
effect of therapy was more in Group A in 
comparison to Group B. 
It is may be due to the Ingredients of 
Hingvadi churna are mainly Katu-tikt Rasa, Ushna 
Virya and having Sukshma, Snigdha and Vikasi Guna 
which are the properties of Vatanulomana 
(facilitator of downward movement of Vata), Shoola 
prashamana (colic pain reliever) and Vedana 
sthapana. 
The drug Hingvadi Churna provided relief in 
all the cardinal features of Kashtartava. All 15 
patients in Group A showed improvement in 
symptoms of Kashtartava as most of the parameters 
were statistically significant. Improvement in 
associated symptoms of diarrhea was statistically 
insignificant. Presence of associated symptoms like 
nausea, vomiting, faintness, diarrhea etc. indicate 
the involvement of other Doshas also in 
Kashtartava. 
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In Group B, Highly significant results are 
shown on Pain Intensity, Pain Duration, Nature of 
Pain, Associated symptoms, VAS Scale. Significant 
results obtained on Flow Amount. Results on Flow 
Duration were insignificant. Highly significant 
results are shown on Nausea and Sweat. Significant 
results obtained on Vomiting, Fatigue, Headache, 
Constipation, Vaginal discharge and Breast 
tenderness while Results on Fainting and Diarrhoea 
were insignificant. 
It is may be due to the fact that Rajah 
Pravirtini Vati has Katu (pungent)-Tikta (bitter) 
Rasa, Laghu (light), Snighdha (unctuous) and 
Tikshna (sharp) Guna, Katu Vipaka and Ushna Virya 
(active potency). Tikta (bitter) taste and Tikshna 
(sharp) property of drug removes the 
Srotoavarodha and facilitates flow of Vata; Katu 
Vipaka and Ushna Virya pacifies the aggravated 
Vata and thus allows the painless flow of Artava.  
CONCLUSION 
Therapeutic Effect of Group-A (Hingvadi churna 
orally) Patients of this group showed relief by 
improvement in 83.33% in pain intensity, 82.85% 
in pain duration, 71.06% in nature of pain, 8.33% in 
menstrual flow duration, 4.54% in menstrual flow 
amount, 74.16% in associated symptoms and 
76.92% in VAS scale. 
Therapeutic Effect of Group-B (Rajah-Pravartini 
Vati orally) Patients of this group showed relief by 
improvement in 53.91% in pain intensity, 54.03% 
in pain duration, 60.00% in nature of pain, -23.08% 
in menstrual flow duration, -26.66% in menstrual 
flow amount, 70.00% in associated symptoms and 
62.14% in VAS scale. 
Comparing the symptomatic improvement in 
both groups it was found that Average percentage 
of relief was higher in Group A i.e. 63.05%, followed 
by Group B i.e., 52.84%. It shows that effect of 
therapy was more in group B in comparison to 
group A. 
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